Logo image of BME

BLACKROCK HEALTH SCIENCES (BME) Stock Overview

USA - NYSE:BME - US09250W1071

37.67 USD
+0.24 (+0.64%)
Last: 10/17/2025, 8:04:00 PM
37.67 USD
0 (0%)
After Hours: 10/17/2025, 8:04:00 PM
Fundamental Rating

2

BME gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 0 industry peers in the Unkown industry. BME has a bad profitability rating. Also its financial health evaluation is rather negative. BME is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BME has reported negative net income.
In the past year BME had a positive cash flow from operations.
BME had positive earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: BME reported negative operating cash flow in multiple years.
BME Yearly Net Income VS EBIT VS OCF VS FCFBME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

1.2 Ratios

Industry RankSector Rank
ROA -4.83%
ROE -5.03%
ROIC 0.16%
ROA(3y)1.06%
ROA(5y)5.33%
ROE(3y)1.07%
ROE(5y)5.44%
ROIC(3y)0.2%
ROIC(5y)0.12%
BME Yearly ROA, ROE, ROICBME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 15

1.3 Margins

BME's Profit Margin has declined in the last couple of years.
In the last couple of years the Operating Margin of BME has remained more or less at the same level.
Industry RankSector Rank
OM 13.92%
PM (TTM) N/A
GM 100%
OM growth 3Y169.88%
OM growth 5Y-0.74%
PM growth 3Y-30.97%
PM growth 5Y-28.42%
GM growth 3YN/A
GM growth 5YN/A
BME Yearly Profit, Operating, Gross MarginsBME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

More info and screens

3

2. Health

2.1 Basic Checks

BME has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, BME has more shares outstanding
Compared to 1 year ago, BME has a worse debt to assets ratio.
BME Yearly Shares OutstandingBME Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
BME Yearly Total Debt VS Total AssetsBME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

BME has an Altman-Z score of 14.27. This indicates that BME is financially healthy and has little risk of bankruptcy at the moment.
BME has a debt to FCF ratio of 0.02. This is a very positive value and a sign of high solvency as it would only need 0.02 years to pay back of all of its debts.
BME has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Although BME does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.02
Altman-Z 14.27
ROIC/WACCN/A
WACCN/A
BME Yearly LT Debt VS Equity VS FCFBME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

BME has a Current Ratio of 0.10. This is a bad value and indicates that BME is not financially healthy enough and could expect problems in meeting its short term obligations.
BME has a Quick Ratio of 0.10. This is a bad value and indicates that BME is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.1
Quick Ratio 0.1
BME Yearly Current Assets VS Current LiabilitesBME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

BME shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -150.26%.
BME shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -24.80% yearly.
Looking at the last year, BME shows a decrease in Revenue. The Revenue has decreased by -6.58% in the last year.
Measured over the past years, BME shows a quite strong growth in Revenue. The Revenue has been growing by 8.91% on average per year.
EPS 1Y (TTM)-150.26%
EPS 3Y-26.89%
EPS 5Y-24.8%
EPS Q2Q%-108.48%
Revenue 1Y (TTM)-6.58%
Revenue growth 3Y5.76%
Revenue growth 5Y8.91%
Sales Q2Q%-2.46%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BME Yearly Revenue VS EstimatesBME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BME reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BME Price Earnings VS Forward Price EarningsBME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF 5.94
EV/EBITDA N/A
BME Per share dataBME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

5

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 7.65%, BME is a good candidate for dividend investing.
Compared to an average S&P500 Dividend Yield of 2.36, BME pays a better dividend.
Industry RankSector Rank
Dividend Yield 7.65%

5.2 History

The dividend of BME has a limited annual growth rate of 3.39%.
BME has paid a dividend for at least 10 years, which is a reliable track record.
BME has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)3.39%
Div Incr Years1
Div Non Decr Years10
BME Yearly Dividends per shareBME Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5 2 2.5

5.3 Sustainability

The earnings of BME are negative and hence is the payout ratio. BME will probably not be able to sustain this dividend level.
DP-148.67%
EPS Next 2YN/A
EPS Next 3YN/A
BME Yearly Income VS Free CF VS DividendBME Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

More info and screens

BLACKROCK HEALTH SCIENCES

NYSE:BME (10/17/2025, 8:04:00 PM)

After market: 37.67 0 (0%)

37.67

+0.24 (+0.64%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)09-03 2025-09-03
Earnings (Next)03-05 2026-03-05
Inst Owners23.81%
Inst Owner Change-0.01%
Ins Owners0%
Ins Owner Change0%
Market Cap486.70M
Analysts0
Price TargetN/A
Short Float %0.14%
Short Ratio0.34
Dividend
Industry RankSector Rank
Dividend Yield 7.65%
Yearly Dividend2.67
Dividend Growth(5Y)3.39%
DP-148.67%
Div Incr Years1
Div Non Decr Years10
Ex-Date10-15 2025-10-15 (0.2621)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 65.15
P/FCF 5.94
P/OCF 5.94
P/B 0.96
P/tB 0.96
EV/EBITDA N/A
EPS(TTM)-1.97
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)6.35
FCFY16.85%
OCF(TTM)6.35
OCFY16.85%
SpS0.58
BVpS39.32
TBVpS39.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.83%
ROE -5.03%
ROCE 0.2%
ROIC 0.16%
ROICexc 0.16%
ROICexgc 0.16%
OM 13.92%
PM (TTM) N/A
GM 100%
FCFM 1097.72%
ROA(3y)1.06%
ROA(5y)5.33%
ROE(3y)1.07%
ROE(5y)5.44%
ROIC(3y)0.2%
ROIC(5y)0.12%
ROICexc(3y)0.2%
ROICexc(5y)0.12%
ROICexgc(3y)0.2%
ROICexgc(5y)0.12%
ROCE(3y)0.25%
ROCE(5y)0.16%
ROICexcg growth 3Y199.74%
ROICexcg growth 5Y4.01%
ROICexc growth 3Y199.74%
ROICexc growth 5Y4.01%
OM growth 3Y169.88%
OM growth 5Y-0.74%
PM growth 3Y-30.97%
PM growth 5Y-28.42%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.02
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.1
Quick Ratio 0.1
Altman-Z 14.27
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-150.26%
EPS 3Y-26.89%
EPS 5Y-24.8%
EPS Q2Q%-108.48%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-6.58%
Revenue growth 3Y5.76%
Revenue growth 5Y8.91%
Sales Q2Q%-2.46%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-38.46%
EBIT growth 3Y185.41%
EBIT growth 5Y8.1%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y432.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y432.12%
OCF growth 3YN/A
OCF growth 5YN/A